F. Asang

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy

C. Klein, S. Endres, S. Kobold, 2018, British Journal of Cancer.

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy

C. Klein, S. Endres, S. Kobold, 2018, British Journal of Cancer.